天疱疮

Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus - an autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990;323:1729-1735.

• 全文
• 摘要

Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 Guideline for diagnosis and treatment - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2015;29:405-414.

• 全文
• 摘要

Frew JW, Murrell DF. Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome). Dermatol Clin. 2011;29:607-612.

• 摘要

Sanchez J, Ingen-Housz-Oro S, Chosidow O, et al. Rituximab as single long-term maintenance therapy in patients with difficult-to-treat pemphigus. JAMA Dermatol. 2018 Mar 1;154(3):363-5.

• 摘要

Ren Z, Narla S, Hsu DY, et al. Association of serious infections with pemphigus and pemphigoid: analysis of the Nationwide Inpatient Sample. J Eur Acad Dermatol Venereol. 2018 May 1;32(10):1768-1776.

• 摘要

1.  Korman N. Pemphigus. J Am Acad Dermatol. 1988;18:1219-1238.

• 摘要

2.  Mutasim DF, Pelc NJ, Anhalt GJ. Paraneoplastic pemphigus. Dermatol Clin. 1993;11:473-481.

• 摘要

3.  Simon DG, Krutchkoff D, Kaslow RA, et al. Pemphigus in Hartford County, Connecticut, from 1972 to 1977. Arch Dermatol. 1980;116:1035-1037.

• 摘要

4.  Langan SM, Smeeth L, Hubbard R, et al. Bullous pemphigoid and pemphigus vulgaris - incidence and mortality in the UK: population based cohort study. BMJ. 2008;337:a180.

• 全文
• 摘要

5.  V'lckova-Laskoska MT, Laskoski DS, Kamberova S, et al. Epidemiology of pemphigus in Macedonia: a 15-year retrospective study (1990-2004). Int J Dermatol. 2007;46:253-258.

• 摘要

6.  Asilian A, Yoosefi A, Faghini G, et al. Pemphigus vulgaris in Iran: epidemiology and clinical profile. Skinmed. 2006;5:69-71.

• 摘要

7.  Bordenave K, Griffith J, Hordes SM, et al. The historical and geomedical immunogenetics of pemphigus among the descendants of Sephardic Jews in New Mexico. Arch Dermatol. 2001;137:825-826.

• 摘要

8.  Hans-Filho G, dos Santos V, Katayama JH, et al. An active focus of high prevalence of fogo selvagem on an Amerindian reservation in Brazil. Cooperative Group on Fogo Selvagem Research. J Invest Dermatol. 1996;107:68-75.

• 摘要

9.  Kottke MD, Delva E, Kowalczyk AP. The desmosome: cell science lessons from human diseases. J Cell Sci. 2006;119:797-806.

• 全文
• 摘要

10.  Becker BA, Gaspari AA. Pemphigus vulgaris and vegetans. Dermatol Clin. 1993;11:429-452.

• 摘要

11.  Crosby DL, Diaz LA. Endemic pemphigus foliaceus. Fogo selvagem. Dermatol Clin. 1993;11:453-462.

• 摘要

12.  Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus - an autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990;323:1729-1735.

• 全文
• 摘要

13.  Diaz LA, Sampaio SA, Rivitti EA, et al. Endemic pemphigus foliaceus (fogo selvagem): II. Current and historical epidemiological aspects. J Invest Dermatol. 1989;92:4-12.

• 摘要

14.  Aoki V, Millikan RC, Diaz LA, et al. Environmental risk factors in pemphigus foliaceus (fogo selvagem). J Investig Dermatol Symp Proc. 2004;9:34-40.

• 摘要

15.  Qian Y, Jeong JS, Maldonado M, et al. Brazilian pemphigus foliaceus anti-desmoglein 1 autoantibodies cross-react with sand fly salivary LJM11 antigen. J Immunol. 2012;189:1535-1539.

• 全文
• 摘要

16.  Takahashi Y, Patel HP, Labib RS, et al. Experimentally induced pemphigus vulgaris in neonatal BALB/c mice: a time-course study of clinical, immunologic, ultrastructural, and cytochemical changes. J Invest Dermatol. 1985;84:41-46.

• 摘要

17.  Tan-Lim R, Bystryn JC. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies. J Am Acad Dermatol. 1990;22:35-40.

• 摘要

18.  Yancey KB. The pathophysiology of autoimmune blistering diseases. J Clin Invest. 2005;115:825-828.

• 摘要

19.  Mahoney MG, Wang Z, Rothenberger K, et al. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest. 1999;103:461-468.

• 摘要

20.  Craft J, Fatenejad S. Self antigens and epitope spreading in systemic autoimmunity. Arthritis Rheum. 1997;40:1374-1382.

• 摘要

21.  Billet SE, Grando SA, Pittelkow MR. Paraneoplastic autoimmune multiorgan syndrome: review of the literature and support for a cytotoxic role in pathogenesis. Autoimmunity. 2006;36:617-630.

• 摘要

22.  Brenner S, Goldberg I. Drug-induced pemphigus. Clin Dermatol. 2011;29:455-457.

• 摘要

23.  Nousari HC, Deterding R, Wojtczack H, et al. The mechanism of respiratory failure in paraneoplastic pemphigus. N Engl J Med. 1999;340:1406-1410.

• 摘要

24.  Abasq C, Mouquet H, Gilbert D, et al. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. Arch Dermatol. 2009;145:529-535.

• 全文
• 摘要

25.  Cummins DL, Mimouni D, Tzu J, et al. Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies. J Am Acad Dermatol. 2007;56:153-159.

• 摘要

26.  Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 Guideline for diagnosis and treatment - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2015;29:405-414.

• 全文
• 摘要

27.  Martin LK, Werth VP, Villaneuva EV, et al. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol. 2011;64:903-908.

• 摘要

28.  Frew JW, Murrell DF. Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome). Dermatol Clin. 2011;29:607-612.

• 摘要

29.  Czernik A, Camilleri M, Pittelkow MR, et al. Paraneoplastic autoimmune multiorgan syndrome: 20 years after. Int J Dermatol. 2011;50:905-914.

• 摘要

30.  Beissert S, Mimouni D, Kanwar AJ, et al. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol. 2010;130:2041-2048.

• 摘要

31.  Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol. 2006;142:1447-1454.

• 摘要

32.  Kawashita MY, Tsai K, Aoiki V, et al. Mycophenolate mofetil as an adjuvant therapy for classic and endemic pemphigus foliaceus. J Dermatol. 2005;32:574-580.

• 摘要

33.  Hertl M, Zillikens D, Borradori L, et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges. 2008;6:366-373.

• 全文
• 摘要

34.  Sanchez J, Ingen-Housz-Oro S, Chosidow O, et al. Rituximab as single long-term maintenance therapy in patients with difficult-to-treat pemphigus. JAMA Dermatol. 2018 Mar 1;154(3):363-5.

• 摘要

35.  Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357:545-552.

• 全文
• 摘要

36.  Ahmed AR, Spigelman Z, Cavacini LA, et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355:1772-1779.

• 全文
• 摘要

37.  Gurcan HM, Jeph S, Ahmed AR, et al. Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering diseases: a review of the evidence for its efficacy and safety. Am J Clin Dermatol. 2010;11:315-326.

• 摘要

38.  Peterson JD, Chan LS. Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: a comprehensive survey of 71 consecutive patients from the initial use to 2007. Ther Clin Risk Manag. 2009;5:1-7.

• 全文
• 摘要

39.  Nard FD, Todoerti M, Grosso V, et al. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: extending perspective from old to newer drugs. World J Hepatol. 2015;7:344-361.

• 全文
• 摘要

40.  Mutasim DF. Therapy of autoimmune bullous diseases. Ther Clin Risk Manag. 2007;3:29-40.

• 全文
• 摘要

41.  Aoyama Y, Nagasawa C, Nagai M, et al. Severe pemphigus vulgaris: successful combination therapy of plasmapheresis followed by intravenous high-dose immunoglobulin to prevent rebound increase in pathogenic IgG. Eur J Dermatol. 2008;18:557-560.

• 摘要

42.  Schmidt E, Zillikens D. Immunoadsorption in dermatology. Arch Dermatol Res. 2010;302:241-253.

• 摘要

43.  Kardos M, Levine D, Gürcan HM, et al. Pemphigus vulgaris in pregnancy: analysis of current data on the management and outcomes. Obstet Gynecol Surv. 2009;64:739-749.

• 摘要

44.  Ekbäck M, Uggla B. Paraneoplastic pemphigus associated with chronic lymphocytic leukaemia: treatment with alemtuzumab. Leuk Res. 2012;36:e190-e191.

• 摘要

45.  Ellebrecht CT, Choi EJ, Allman DM, et al. Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris. JAMA Dermatol. 2014;150:1331-1335.

• 摘要

46.  Colliou N, Picard D, Caillot F, et al. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med. 2013;5:175ra30.

• 摘要

47.  Leger S, Picard D, Ingen-Housz-Oro S, et al. Prognostic factors of paraneoplastic pemphigus. Arch Dermatol. 2012;148:1165-1172.

• 全文
• 摘要

48.  Ren Z, Narla S, Hsu DY, et al. Association of serious infections with pemphigus and pemphigoid: analysis of the Nationwide Inpatient Sample. J Eur Acad Dermatol Venereol. 2018 May 1;32(10):1768-1776.

• 摘要